India's New IPR Policy: Balanced And Evolving?
India new National Intellectual Property Rights (IPR) policy appears to have steered clear of a host of prickly issues pertaining to the pharmaceutical industry for now while standing firm on the need for "strong measures" against attempts to treat generic drugs as "spurious or counterfeit".
You may also be interested in...
As Novartis continues to battle Glivec-related pain in India, its country president Jawed Zia tells Scrip that the Swiss multinational has been hit "particularly hard" after the government withdrew customs duty exemptions on more than 70 drugs including imatinib mesylate earlier this year.
India appears to be on course to releasing its National Intellectual Property Rights (IPR) policy but some industry experts say they are concerned that, despite seeming assurances, concessions around "patent linkage" and "data exclusivity" may find their way into the final framework.
India's draft national intellectual property rights (IPR) policy, which appears to steer clear from very radical suggestions, is aiming to strengthen the enforcement and adjudicatory mechanisms for combating IP violations, piracy and counterfeiting to facilitate effective and quick resolution of disputes.